Pediatrix Medical Group, Inc. - 10-Q Summary (Q1 2006)
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2006. Pediatrix Medical Group, Inc. operates as a national provider of pediatric medical services through affiliated professional contractors. The financial statements reflect the impact of a two-for-one stock split authorized on April 4, 2006, and the adoption of FAS 123R (Share-Based Payment) effective January 1, 2006.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Patient Service Revenue | $187.7 million | $164.2 million |
| Net Income | $23.8 million | $18.0 million |
| Diluted EPS | $0.49 | $0.38 |
| Operating Margin | 20.1% | 17.9% |
| Cash and Cash Equivalents | $4.5 million | $4.1 million |
| Working Capital | $34.5 million | ($2.2 million deficit) |
| Line of Credit Outstanding | $41.0 million | $28.0 million (borrowed) |
Note: Cash flow from operating activities was negative $11.2 million in Q1 2006 compared to positive $0.7 million in Q1 2005, primarily due to working capital changes and accounting presentation shifts.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14.3% year-over-year. Approximately 52.3% of this increase ($12.3 million) was attributable to acquisitions completed after December 31, 2004. Same-unit revenue grew 6.9%.
- Profitability: Net income increased 32.1%. The prior year (2005) results were negatively impacted by a $6.0 million liability reserve for Medicaid/Tricare investigations, whereas the current year (2006) results include a $5.0 million equity-based compensation expense due to FAS 123R adoption.
- Acquisitions: The company acquired three physician group practices in Q1 2006, recording $62.1 million in goodwill.
- Working Capital: Working capital improved significantly from a $2.2 million deficit to a $34.5 million surplus, driven by stock option exercises and line of credit borrowings offsetting acquisition costs.
Guidance, Outlook, and Risks
- Accounting Changes: The adoption of FAS 123R resulted in a $5.0 million equity-based compensation expense in Q1 2006, reducing net income by approximately $3.1 million after-tax. This is a recurring expense expected to impact future financial statements.
- Legal Contingencies: On February 8, 2006, the company reached an agreement in principle to settle federal and state Medicaid/Tricare billing investigations. Reserves were increased to $25.1 million. While the financial portion is agreed upon, a final settlement agreement is not yet executed.
- Liquidity: The company maintains a $225 million line of credit (maturing July 2009). With $41.0 million outstanding and $16.0 million in letters of credit, sufficient liquidity is expected to fund operations and acquisitions for the next 12 months.
- Stock Split: A two-for-one stock split was executed in April 2006; all historical share and per-share data in this report have been adjusted to reflect this split.
Investor Verification Checklist
- Settlement Finalization: Verify the execution of the final settlement agreement regarding the Medicaid/Tricare investigations to confirm the $25.1 million reserve is final.
- Acquisition Integration: Monitor the revenue contribution and integration costs of the three practices acquired in Q1 2006.
- Equity Compensation Impact: Track the ongoing impact of FAS 123R on operating margins and net income in subsequent quarters.
- Cash Flow Trends: Review the sustainability of negative operating cash flows in Q1, which are seasonal but exacerbated by the timing of incentive payments and working capital shifts.
- Debt Covenants: Confirm continued compliance with the financial covenants of the $225 million line of credit, specifically regarding net worth and leverage ratios.